Brooklyn ImmunoTherapeutics Inc. [AMEX: BTX] stock went on an upward path that rose over 27.31% on Tuesday, amounting to a one-week price increase of more than 64.81%. The company report on April 20, 2021 that Brooklyn ImmunoTherapeutics Reports Inducement Grants.
Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, announced that on 16 April 2021, Dr. Federoff was granted a nonqualified stock option covering 2,627,915 shares of Brooklyn’s common stock (the “Time-Based Option”).
The Time-Based Option will have a per share exercise price equal to the closing price of a share of Brooklyn’s common stock on the NYSE American Stock Exchange on 16 April 2021. Of the shares covered by the Time-Based Option, 656,979 will vest on April 16, 2022, 54,748 will vest on the sixteenth day of each month from May 2022 through March 2025, and the remaining 54,756 will vest on April 16, 2025, in each case for so long as the Dr. Federoff provides continuous service to Brooklyn through the relevant vesting date.
Over the last 12 months, BTX stock rose by 325.65%.
The market cap for the stock reached $324.54 million, with 1.48 million shares outstanding. Compared to the average trading volume of 1.86M shares, BTX stock reached a trading volume of 6142647 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Brooklyn ImmunoTherapeutics Inc. [BTX]:
The Average True Range (ATR) for Brooklyn ImmunoTherapeutics Inc. is set at 1.45, with the Price to Sales ratio for BTX stock in the period of the last 12 months amounting to 55.95. The Price to Book ratio for the last quarter was 16.88, with the Price to Cash per share for the same quarter was set at 0.02.
BTX Stock Performance Analysis:
Brooklyn ImmunoTherapeutics Inc. [BTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 64.81. With this latest performance, BTX shares gained by 38.67% in over the last four-week period, additionally plugging by 127.67% over the last 6 months – not to mention a rise of 325.65% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BTX stock in for the last two-week period is set at 65.09, with the RSI for the last a single of trading hit 73.25, while it was recorded at 7.57 for the last single week of trading.
Insight into Brooklyn ImmunoTherapeutics Inc. Fundamentals:
Brooklyn ImmunoTherapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.70.
Brooklyn ImmunoTherapeutics Inc. [BTX] Insider Position Details
There are presently around $1 million, or 0.20% of BTX stock, in the hands of institutional investors. The top three institutional holders of BTX stocks are: EAGLE ASSET MANAGEMENT INC with ownership of 35,162, which is approximately New of the company’s market cap and around 0.50% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 10,590 shares of the stock with an approximate value of $81000.0 in BTX stocks shares; and NORTH STAR INVESTMENT MANAGEMENT CORP., currently with $73000.0 in BTX stock with ownership of nearly 0% of the company’s market capitalization.
4 institutional holders increased their position in Brooklyn ImmunoTherapeutics Inc. [AMEX:BTX] by around 44,679 shares. Additionally, 4 investors decreased positions by around 63,564 shares, while 7 investors held positions by with 33,733 shares. The mentioned changes placed institutional holdings at 74,510 shares, according to the latest SEC report filing. BTX stock had 3 new institutional investments in for a total of 43,993 shares, while 4 institutional investors sold positions of 63,564 shares during the same period.